Differences in clinical outcomes in patients with vancomycin-resistant enterococci according to linezolid susceptibility

Pharmacotherapy

Volumn 30, Issue 12, 2010, Pages 1221-1228

  Scheetz, Marc H ^a,b   Knechtel, Stephanie A ^a   Postelnick, Michael J ^a   Malczynski, Michael ^a   Qi, Chao ^a  

^a NORTHWESTERN MEMORIAL HOSPITAL   (United States)

^b MIDWESTERN UNIVERSITY   (United States)

Author keywords

Antibiotic resistance; Enterococcus; G2576T; Linezolid resistance; Vancomycin resistant enterococci; VRE

Indexed keywords

ANTIBIOTIC AGENT; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; LINEZOLID; VANCOMYCIN;

ADULT; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL INFECTION; BACTERIUM CULTURE; BACTERIUM ISOLATION; COHORT ANALYSIS; ECHOCARDIOGRAPHY; ENTEROCOCCUS; GENE MUTATION; HOSPITALIZATION; HUMAN; INTENSIVE CARE UNIT; LENGTH OF STAY; MAJOR CLINICAL STUDY; MEDICAL RECORD REVIEW; MORTALITY; MULTIVARIATE ANALYSIS; NONHUMAN; OUTCOMES RESEARCH; POLYMERASE CHAIN REACTION; RETROSPECTIVE STUDY; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; VANCOMYCIN RESISTANT ENTEROCOCCUS;

ACETAMIDES; AGED; ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; ENTEROCOCCUS; FEMALE; HUMANS; MALE; MIDDLE AGED; MUTATION; OXAZOLIDINONES; RETROSPECTIVE STUDIES; RISK FACTORS; TREATMENT OUTCOME; VANCOMYCIN RESISTANCE;

EID: 78650215775     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.30.12.1221     Document Type: Article

References (21)

1. Swaney SM, Aoki H, Ganoza MC, Shinabarger DL. The oxazolidinone linezolid inhibits initiation of protein synthesis in bacteria. Antimicrob Agents Chemother 1998;42:3251-5.
2. Gonzales RD, Schreckenberger PC, Graham MB, Kelkar S, DenBesten K, Quinn JP. Infections due to vancomycin-resistant Enterococcus faecium resistant to linezolid [letter]. Lancet 2001;357:1179.
3. Mutnick AH, Enne V, Jones RN. Linezolid resistance since 2001: SENTRY antimicrobial surveillance program. Ann Pharmacother 2003;37:769-74.
4. Raad I, Hanna HA, Hachem RY, et al. Clinical-use-associated decrease in susceptibility of vancomycin-resistant Enterococcus faecium to linezolid: a comparison with quinupristin-dalfopristin. Antimicrob Agents Chemother 2004;48:3583-5.
5. Scheetz MH, Knechtel SA, Malczynski M, Postelnick MJ, Qi C. Increasing incidence of linezolid-intermediate or -resistant, vancomycin-resistant Enterococcus faecium strains parallels increasing linezolid consumption. Antimicrob Agents Chemother 2008;52:2256-9. (Pubitemid 351758573)
6. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; nineteenth informational supplement, M100-S19. Wayne, PA: Clinical and Laboratory Standards Institute, 2009.
7. Meka VG, Gold HS. Antimicrobial resistance to linezolid. Clin Infect Dis 2004;39:1010-15.
8. Prystowsky J, Siddiqui F, Chosay J, et al. Resistance to linezolid: characterization of mutations in rRNA and comparison of their occurrences in vancomycin-resistant enterococci. Antimicrob Agents Chemother 2001;45:2154-6. (Pubitemid 32591718)
9. Ruggero KA, Schroeder LK, Schreckenberger PC, Mankin AS, Quinn JP. Nosocomial superinfections due to linezolidresistant Enterococcus faecalis: evidence for a gene dosage effect on linezolid MICs. Diagn Microbiol Infect Dis 2003;47:511-13.
10. Jones RN, Moet GJ, Woosley L, Sader HS, Fritsche TR. Critical evaluation of linezolid susceptibility testing using two automated systems (Vitek, Vitek2) [abstract]. In: Program and abstracts of the 47th interscience conference on antimicrobial agents and chemotherapy. Washington, DC: American Society for Microbiology, 2007:abstract D-225.
11. Qi C, Zheng X, Obias A, Scheetz MH, Malczynski M, Warren JR. Comparison of testing methods for detection of decreased linezolid susceptibility due to G2576T mutation of the 23s rRNA gene in Enterococcus faecium and Enterococcus faecalis. J Clin Microbiol 2006;44:1098-100.
12. Tenover FC, Williams PP, Stocker S, et al. Accuracy of six antimicrobial susceptibility methods for testing linezolid against staphylococci and enterococci. J Clin Microbiol 2007;45:2917-22. (Pubitemid 47417334)
13. Scheetz MH, Qi C, Noskin GA, et al. The clinical impact of linezolid susceptibility reporting in patients with vancomycin-resistant enterococci. Diagn Microbiol Infect Dis 2006;56:407-13.
14. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373-83.
15. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992;45:613-19.
16. Sun GW, Shook TL, Kay GL. Inappropriate use of bivariable analysis to screen risk factors for use in multivariable analysis. J Clin Epidemiol 1996;49:907-16.
17. Pai MP, Rodvold KA, Schreckenberger PC, Gonzales RD, Petrolatti JM, Quinn JP. Risk factors associated with the development of infection with linezolid- and vancomycin-resistant Enterococcus faecium. Clin Infect Dis 2002;35:1269-72.
18. Pogue JM, Paterson DL, Pasculle AW, Potoski BA. Determination of risk factors associated with isolation of linezolid-resistant strains of vancomycin-resistant Enterococcus. Infect Control Hosp Epidemiol 2007;28:1382-8.
19. Kainer MA, Devasia RA, Jones TF, et al. Response to emerging infection leading to outbreak of linezolid resistant enterococci. Emerg Infect Dis 2007;13:1024-30.
20. Harbarth S, Nobre V, Pittet D. Does antibiotic selection impact patient outcome? Clin Infect Dis 2007;44:87-93.
21. Ury HK. Efficiency of case-control studies with multiple controls per case: continuous or dichotomous data. Biometrics 1975;31:643-9.